12/20 #TumorBoardTuesday

💡Mini tweetorial 6.5

🔬Ongoing trials of MDT in de novo oligomets mCSPC (NCT03298087, NCT03784755, NCT03763253, NCT05223803) 📚

NCCN recs ⚡SBRT to oligometas from PCa when (1) goal is ablation (2) limited progression or (3) symptomatic lesion
#TumorBoardTuesday